Ticker Details
Anavex Life Sciences Corp. Anavex Life Sciences Corp is a clinical stage bio-pharmaceutical company. The Company is engaged in the developments drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, and various types of cancer.
IPO Date:	October 7, 2015
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$249.75M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.24 | 3.45%
Avg Daily Range (30 D):	$0.09 | 2.86%
Avg Daily Range (90 D):	$0.12 | 3.06%

Institutional Daily Volume
Avg Daily Volume:	1.04M
Avg Daily Volume (30 D):	.85M
Avg Daily Volume (90 D):	1.18M

Trade Size
Avg Trade Size (Sh.):	153
Avg Trade Size (Sh.) (30 D):	108
Avg Trade Size (Sh.) (90 D):	116

Institutional Trades
Total Institutional Trades:	1,424
Avg Institutional Trade:	$1.46M
Avg Institutional Trade (30 D):	$.57M
Avg Institutional Trade (90 D):	$.96M
Avg Institutional Trade Volume:	.16M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$1.52M
Avg Closing Trade (30 D):	$.57M
Avg Closing Trade (90 D):	$.97M
Avg Closing Volume:	168.5K

News

Dec 24, 2025 @ 3:30 PM AVXL Investors Have Opportunity to Join Anavex Lif... Source: The Schall Law Firm

Dec 4, 2025 @ 12:39 AM AVXL Investors Have Opportunity to Join Anavex Lif... Source: Business Wire

Nov 14, 2025 @ 2:36 PM Anavex Life Sciences Crashes as EMA Setback Sparks... Source: Timothy Fries

Aug 5, 2025 @ 8:26 AM Alzheimer's Disease Disease-Modifying Therapies Ma... Source: Researchandmarkets.Com

Jun 16, 2025 @ 10:38 PM ANAVEX SHAREHOLDER ALERT: Kaskela Law LLC Announce... Source: N/A

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-.06	$-.11	$-.54
Diluted EPS	$-.06	$-.11	$-.54
Revenue	$1.08M	$1M	$4.68M
Gross Profit
Net Income / Loss	$-5.68M	$-9.83M	$-46.38M
Operating Income / Loss	$-6.78M	$-10.84M	$-51.41M
Cost of Revenue
Net Cash Flow	$M	$M	$M
PE Ratio

Splits
Oct 07, 2015	1:4
Jun 12, 2006	6:1